CTLA4 and head and neck squamous cell carcinoma: Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies or anti-CTLA4 antibodies, are another potential pillar of systemic therapy for advanced HNSCC, though with limited clinical evidence.